G1 Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch GTHX and buy or sell other stocks, ETFs, and their options commission-free!

About GTHX

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. 

CEO
Josh Franklin, MBA
CEOJosh Franklin, MBA
Employees
—
Employees—
Headquarters
Research Triangle Park, North Carolina
HeadquartersResearch Triangle Park, North Carolina
Founded
2008
Founded2008
Employees
—
Employees—

GTHX Key Statistics

Market cap
376.79M
Market cap376.79M
Price-Earnings ratio
-8.30
Price-Earnings ratio-8.30
Dividend yield
—
Dividend yield—
Average volume
651.38K
Average volume651.38K
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$7.19
52 Week high$7.19
52 Week low
$1.08
52 Week low$1.08

People also own

Based on the portfolios of people who own GTHX. This list is generated using Robinhood data, and it’s not a recommendation.
Plug Power
NIO
Tilray Brands
Nikola
Ocugen, Inc
Virgin Galactic Holdings
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.